Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 an open-label, randomized, dose-ranging study of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis

Next Previous
X
Search
Trial Profile

Phase 1 an open-label, randomized, dose-ranging study of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Fibroma
  • Focus Adverse reactions

    • Most Recent Events

    • 18 Oct 2024 According to an Endo Inc. media release, data from this trial will be presented during the American Society of Podiatric Surgeons (ASPS) Surgical Conference, taking place October 18-19, 2024.
    • 18 Oct 2024 According to an Endo, Inc. media release, data from this study will be presented at the American Society of Podiatric Surgeons (ASPS) Surgical Conference, taking place October 18-19, 2024.
    • 21 Sep 2023 According to Endo International Media Release, data from this study will be presented at the American Orthopaedic Foot & Ankle Society's (AOFAS) annual scientific meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top